Is a complete VKTX research report available?

No complete published report is available for Viking Therapeutics, Inc. (VKTX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Viking Therapeutics, Inc. (VKTX)

NASDAQ: VKTX · USD

$34.9

+0.08 (+0.2%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-28 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first VKTX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	4B
Net income (ttm)	-472.3M
EPS (ttm)	-$4.16
Shares out	116.1M
Volume	1,890,012
Beta	0.66
Price target	$92.6	+165.5%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -472.3M
EPS (ttm): -$4.16
Market cap: 4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All VKTX indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001607678
Company name	Viking Therapeutics, Inc.
Country	United States
Country code	US
Cusip	92686J106
Employees	59
Employees Change	13%
Employees Change Percent	28.26
Enterprise value	$3.4B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2015-04-29
Isin	US92686J1060
Last refreshed	2026-07-28
Market cap	$4B
Market cap category	Mid-Cap
Price	$34.87
Price currency	USD
Sector	Healthcare
Sector PE	45.29
Sector PE Fwd	23.97
Sic	2834
Symbol	VKTX
Website	https://www.vikingtherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-11.67%
P/B ratio	8.05x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-472.3M
Net Income Growth Years	0%
Profit Per Employee	$-8M
ROA	-42.54
Roa5y	-21.32
ROCE	-100
ROE	-70.04
Roe5y	-32.87
ROIC	-46.49

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	38.33%
Cagr1y	1.31%
Cagr3y	34.65%
Cagr5y	44.02%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$608.2M
Cash	$603M
Current Assets	$608.2M
Current Liabilities	$106.3M
Debt	$0
Equity	$501.9M
Interest Coverage	-15,687.4
Liabilities	$106.3M
Long Term Assets	$33,000
Long Term Liabilities	$0
Net Cash	$603M
Net Cash By Market Cap	$14.89
Net Cash Growth	-29.13%
Net Debt Equity	$-1.2
Tangible Book Value	$501.9M
Tangible Book Value Per Share	$4.33
WACC	7.85

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.72
Net Working Capital	$-101.1M
Quick ratio	5.67
Working Capital	$501.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-2.12%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	2,463.97%
1Y total return	1.31%
200-day SMA	33.81
3Y total return	144.19%
50-day SMA	33.75
50-day SMA vs 200-day SMA	50under200
5Y total return	519.36%
All Time High	99.41
All Time High Change	-64.92%
All Time High Date	2024-02-28
All Time Low	0.88
All Time Low Change	3,862.5%
All Time Low Date	2017-08-02
ATR	1.94
Beta	0.66
Beta1y	0.95
Beta2y	1.17
Ch YTD	-0.88
High	36.12
High52	43.15
High52 Date	2025-11-12
High52ch	-19.19%
Low	34.64
Low52	22.96
Low52 Date	2025-09-17
Low52ch	51.88%
Ma50ch	3.32%
Premarket Change Percent	1.67
Premarket Price	$35.37
Premarket Volume	7,065
Price vs 200-day SMA	3.14%
RSI	45.29
RSI Monthly	50.57
RSI Weekly	52.67
Sharpe ratio	0.42x
Sortino ratio	0.62
Total Return	-2.12%
Tr YTD	-0.88
Tr1m	-8.33%
Tr1w	-4.15%
Tr3m	6.47%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	20
Analyst Count Top	9
Analyst Price Target Top	$97.57
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.21
Operating Income	$-502M
Price target	$92.58
Price Target Change	$166
Price Target Change Top	$180

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	113,280,386%
Float Percent	97.57%
Shares Insiders	2.39%
Shares Institutions	63.71%
Shares Out	116,105,643
Shares Qo Q	1.37%
Shares Yo Y	2.12%
Short Float	20.45%
Short Ratio	7.98
Short Shares	19.95

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted OCF	-380,137,000
Average Volume	2,247,164.2x
Bv Per Share	4.33
Ch10y	2,464
Ch1m	-8.33
Ch1w	-4.15
Ch1y	1.31
Ch3m	6.47
Ch3y	144.2
Ch5y	519.4
Ch6m	9.9
Change	0.23%
Change From Open	-1.52
Close	34.79
Days Gap	1.78
Depreciation Amortization	405,000
Dollar Volume	65,904,718.4
Earnings Date	2026-07-29
Earnings Time	amc
EBIT	$-502M
EBITDA	$-501.6M
EPS	$-4.16
F Score	1
Financing CF	88,167,000
Fiscal Year End	December
Founded	2,012
Investing CF	332,332,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-11
Ma150	33.1
Ma150ch	5.33%
Ma20	37.92
Ma20ch	-8.03%
Net CF	80,176,000
Next Earnings Date	2026-07-29
Open	35.41
Optionable	Yes
Position In Range	15.54
Post Close	34.87
Postmarket Change Percent	0.37
Postmarket Price	$35
Pre Close	34.79
Price Date	2026-07-27
Ptbv Ratio	8.07
Relative Volume	0.84x
Share Based Comp	39,807,000
Tr6m	9.9%
Us State	California
Volume	1,890,012

Viking Therapeutics, Inc. (VKTX)

Coverage state: Market snapshot only — no published research

Generate the first VKTX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · VKTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All VKTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on VKTX

Frequently asked questions